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The difficulty in clinical assessment of patients with ovarian cancer has led to a search -for a sensitive tumour marker. The tumour associated antigen CA125 is thought to be the most useful currently available Milford Ward, 1987) . It is present in the tumour tissue of over 80% of ovarian carcinomas at first laparotomy (Kabawat et al., 1983; Koelma et al., 1987; Maughan et al., 1988) . Serum antigen levels are elevated in over 60% of patients and appear to correlate with the clinical course of the disease Canney et al., 1984; Fish et al., 1987) . Elevated serum levels after chemotherapy have been found to predict for the presence of residual disease at second laparotomy (Niloff et al., 1985; Alvarez et al., 1987; Fish et al., 1987) . However, one limitation of serum CA125 monitoring is that the majority of patients with serum levels falling into the normal range after chemotherapy still have residual disease at second laparotomy (Niloff et al., 1985; Fish et al., 1987) . The reason for this phenomenon is unclear but one possibility is that chemotherapy selectively kills tumour cells that produce CA125. In order to investigate this, the present study examines tumour material from patients with residual disease at second laparotomy and compares antigenic staining before and after chemotherapy.
Thirteen patients (mean age 52.7 years), who had residual tumour after first laparotomy (lap 1), received 5-monthly courses of platinum therapy (cisplatin 100mg m -2 in 11, carboplatin 400 mg m-2 in two). Thereafter they had no detectable disease on clinical and ultrasound examination and were assessed at a second laparotomy (lap 2). The patients were reclassified according to the findings at lap 2 as having residual disease of 2-10cm (n=4), <2cm (n=7) Table I .
The presence of CA125 was assessed on formalin-fixed, paraffin-embedded tumour tissue from first and second laparotomies using an avidin-biotin-peroxidase technique (Koelma et al., 1987 (Shelley & Fish, 1986 ) which used the same monoclonal antibody (OC 125) as in the immunoperoxidase methodology. The upper limit of the normal serum concentration was taken as 35 units ml-1 ).
CA125 was detected in tumour tissue or peritoneal washings in all 13 patients from lap 1 and in 12 from lap 2 with widespread staining (+ + +) in the majority of cases. Analysis of multiple sections from three patients showed widespread antigen staining in all sections from two cases, with no discernible alteration in pattern or intensity of staining from first to second laparotomies (patients 2, 10). Patient 13 showed a heterogeneous pattern, with areas of positive staining on five of 15 sections, but focal areas of positivity could be detected in tissue both before and after chemotherapy.
Serum antigen levels were elevated after lap I in 10 patients and, during chemotherapy, remained elevated in six III  IV  IV  III  III  III  III  IV  III  III  III  IV but fell into the normal range in four cases. The remaining three patients, each of whom had less than 2cm residuum after lap 1, had normal serum CA125 levels initially. All six patients in whom serum CA125 concentrations were in the normal range before their second laparotomy had CA125 detected in tumour tissue removed at lap 2. The false-negative serum CA125 results are therefore not due to the irradication of antigen-producing cells by chemotherapy, as may occur following chemotherapy in testicular teratomas (Raghavan et al., 1980) . It has been suggested that the epithelial basement membrane provides an effective barrier to the passage of CA125 from the tumour to the serum . The high molecular weight of the antigen (over 500,000 daltons) (Niloff et al., 1985) in the presence of poor tumour blood flow and intact basement membranes around tumour acini is the most likely cause of normal serum CA125 concentrations in the presence of antigen-rich residual tumour at second laparotomy.
